Assistance Publique-Hopitaux De Paris

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Sorbonne Université

Université Paris Est Creteil Val De Marne

Ose Immunotherapeutics

Etablissement Francais Du Sang

Université Pierre Et Marie Curie

Universite Paris Xii

José Cohen

David Klatzmann

Nicolas Poirier

Bernard Vanhove

Mathieu Leclerc

Sebastien Maury

Sina Naserian

François Lemoine

Sébastien Maury

Caroline Pilon

Brigitte Birebent

Benoît Salomon

The invention relates to methods and preparations for sorting out T effector cells from human leukocytes using anti-CD127 antibodies. Accordingly the invention relates to the use of anti-CD127 antibodies enabling discriminative depletion of subpopulations of Tregulatory cells expressing CD127+ at low levels in a population of human T lymphocytes in order to enable the use of the recovered selected cell preparations comprising essentially Teffector cells as lymphocytes and preferably devoid of Tregulatory cells, for improved efficacy in particular when administered to a patient for therapy.

Method effector cells using anti-CD127 antibodies for applications in cell therapy

The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist

Growing community of inventors

Paris, France

José Cohen